| Aqua Bio Technology Signs Clinical Trial Research Agreement With Access Business Group |
|
|
|
|
Strategro client Aqua Bio Technology ASA (ABT), which develops and markets patented advanced marine‐based ingredients to the personal care industry, has signed an agreement with Access Business Group, a sister company to Amway, to jointly perform a clinical trial of ABT’s ingredient Zonase X™. A successful clinical trial could lead the two companies to negotiate a licensing agreement that would feature ABT’s ingredient in Amway’s ARTISTRY® skincare lines (www.artistry.com ).
Amway is one of the world’s largest direct selling businesses with a network of 3 million independent distributors in more than 80 countries and territories, and revenue of USD 8.4 billion. Access Business Group develops and manufactures Amway’s leading product brands: NUTRILITE® vitamin, mineral and dietary supplements, ARTISTRY skincare and colour cosmetics products, and eSpring ®water treatment systems. As part of the clinical trial, Zonase X’s effectiveness towards several new anti‐aging applications will be tested and documented. As part of the agreement, Access Business Group and Amway will co‐fund clinical proof of concept test in exchange for the option for limited global market exclusivity related to certain marketing claims. “We see Zonase X as an innovative ingredient that can be a valuable addition to Amway’s ARTISTRY skincare product portfolio,” said J.C. Leverett, senior research scientist in Health & Beauty New Technology, Access Business Group. “We are eager to explore its potential in antiaging product applications.” “This is an important agreement and milestone for our company”, said Arvid Lindberg, CEO of Aqua Bio Technology. “Entering into this partnership with such a globally‐recognised industrial group as Amway represents a real breakthrough for ABT and provides a strong basis for further commercialization of ABT’s products globally. ABT has so far been focusing successfully on the exfoliating properties of its product Zonase X in their commercialisation of the ingredient, and as this agreement targets specific marketing claims on anti‐aging, we are now expanding our market as we add new application areas for this unique product,” added Lindberg. |